Drug Profile

NL CVX1

Alternative Names: CTC-445.2d; NL-CVX1

Latest Information Update: 26 Dec 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Neoleukin Therapeutics
Developer Neurogene Inc
Class Antivirals; Proteins
Mechanism of Action Virus attachment inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Suspended COVID 2019 infections

Most Recent Events

19 Dec 2023 Neurogene Inc has merged with Neoleukin Therapeutics to form Neurogene Inc
29 Sep 2021 Pharmacodynamics data from a preclinical study in COVID-2019 infections presented at the IDWeek 2021
29 Sep 2021 Pharmacodynamics data from a preclinical studies in COVID-2019 infections presented at the IDWeek 2021

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com